HONG KONG – Astrazeneca plc has won two new approvals from Japan's PMDA for its Lynparza (olaparib) in breast cancer as well as chemotherapy maintenance drug Imfinzi (durvalumab), a further sign that the country is getting faster in approving these drugs, reflecting an urgency in accessing newer cancer treatments.